Need professional-grade analysis? Visit stockanalysis.com
$1.66B
N/A
60
N/A
Price Chart
Risk-Adjusted Performance
Enliven Therapeutics Inc. (ELVN) Price Performance
Enliven Therapeutics Inc. (ELVN) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $48.11, up 6.11% from the previous close.
Over the past year, ELVN has traded between a low of $15.14 and a high of $48.11. The stock has gained 167.7% over this period. It is currently 217.8% above its 52-week low.
Enliven Therapeutics Inc. has a market capitalization of $1.66B.
About Enliven Therapeutics Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Compare Enliven Therapeutics Inc.
Side-by-side comparison against top Healthcare peers.
Company Info
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- United States
- Currency
- USD
- Country
- United States
Financial Metrics
- Revenue (TTM)
- N/A
- EBITDA
- $-119,395,000
- Profit Margin
- N/A
- EPS (TTM)
- -1.73
- Book Value
- 7.73
Technical Indicators
- 52 Week High
- $48.53
- 52 Week Low
- $14.79
- 50 Day MA
- $26.25
- 200 Day MA
- $21.68
- Beta
- 1.06
Valuation
- Trailing P/E
- N/A
- Forward P/E
- N/A
- Price/Sales
- N/A
- Price/Book
- 3.61
- Enterprise Value
- $1.59B